The Therapeutic Effect of Different Doses of Capecitabine

Status Completed

Clinical Trial Summary

To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.Different administration regimens of capecitabine were given, and the treatment course was appropriately extended. The therapeutic effect and incidence of adverse reactions were observed.

Clinical Trial Description

To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group. Afterward, the response rate, quality of life, and adverse reactions of the three groups were collected for comparison. ;

Study Design

Related Conditions & MeSH terms

Capecitabine

Clinical Trial Details

NCT number	NCT06246461
Study type	Interventional
Source	Jingjiang People's Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2022
Completion date	January 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03079427` - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma	Phase 2
Completed	`NCT03079440` - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT05290194` - Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma	Phase 2
Not yet recruiting	`NCT03889626` - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer	Phase 3
Recruiting	`NCT06169202` - A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Not yet recruiting	`NCT05841134` - Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer	Phase 2
Recruiting	`NCT05970302` - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC	Phase 2
Recruiting	`NCT05022030` - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes	Phase 2
Recruiting	`NCT06202014` - Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC	Phase 2
Enrolling by invitation	`NCT03030508` - Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients	N/A
Recruiting	`NCT02012634` - Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer	Phase 3
Active, not recruiting	`NCT06188000` - Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine	N/A
Completed	`NCT04720131` - Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.	Phase 2
Active, not recruiting	`NCT03258099` - Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting	`NCT05535413` - UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases	Phase 1/Phase 2
Active, not recruiting	`NCT03500380` - A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases	Phase 2/Phase 3
Recruiting	`NCT06405490` - NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC	Phase 2